Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of AEF0217 in healthy volunteers
NCT05170737Phase 1Completed
- Sponsor
- Aelis Farma
- Start
- Oct 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AEF0217 in Down syndrome (3 arms), sponsored by Aelis Farma. Primary endpoints: Incidence of treatment-emergent AEs and SAEs as assessed by vital signs, Incidence of treatment-emergent AEs and SAEs as assessed by ECGs and 2 more. Started Oct 2021; status: completed.
02
Drugs
AEF0217
03
Conditions
Down syndrome
Beyond the preview
Go deeper on NCT05170737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05170737.